IP Library Granted Patent US 11,371,046
Granted Patent B2
US 11,371,046 · App. 15/270,578 · Granted Jun 28, 2022

Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors

Inventors: Mark J. Burk (San Diego, CA); Stephen J. Van Dien (San Diego, CA); Anthony P. Burgard (Bellefonte, PA); Wei Niu (Lincoln, NE)
Assignee: Genomatica, Inc.
C12N15/52B01D3/002C12N9/0006C12N9/0008C12N9/88C12N9/93C12N15/70C12N15/81C12P7/18C12P7/42C12P7/52C12P17/04C12Y101/01061C12Y102/01076C12Y401/01071C12Y602/01004Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,371,046
App. No.
15/270,578
Granted
Jun 28, 2022
Kind
B2
Abstract

The invention provides a non-naturally occurring microbial biocatalyst including a microbial organism having a 4-hydroxybutanoic acid (4-HB) biosynthetic pathway having at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, or α-ketoglutarate decarboxylase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce monomeric 4-hydroxybutanoic acid (4-HB). Also provided is a non-naturally occurring microbial biocatalyst including a microbial organism having 4-hydroxybutanoic acid (4-HB) and 1,4-butanediol (BDO) biosynthetic pathways, the pathways include at least one exogenous nucleic acid encoding 4-hydroxybutanoate dehydrogenase, succinyl-CoA synthetase, CoA-dependent succinic semialdehyde dehydrogenase, 4-hydroxybutyrate:CoA transferase, 4-butyrate kinase, phosphotransbutyrylase, α-ketoglutarate decarboxylase, aldehyde dehydrogenase, alcohol dehydrogenase or an aldehyde/alcohol dehydrogenase, wherein the exogenous nucleic acid is expressed in sufficient amounts to produce 1,4-butanediol (BDO). Additionally provided are methods for the production of 4-HB and BDO.

Claims (27)

1. A non-naturally occurring microbial organism having a 4-hydroxybutanoic acid (4-HB) biosynthetic pathway, said pathway comprising exogenous nucleic acids encoding a) an α-ketoglutarate decarboxylase, or an α-ketoglutarate dehydrogenase and a CoA-dependent succinic semialdehyde dehydrogenase, or a glutamate:succinate semialdehyde transaminase and a glutamate decarboxylase; and b) a 4-hydroxybutanoate dehydrogenase, wherein said exogenous nucleic acids are expressed and the microbial organism secretes monomeric 4-HB.

2. The non-naturally occurring microbial organism of claim 1 , wherein the exogenous nucleic acids encode a) an α-ketoglutarate decarboxylase, and b) a 4-hydroxybutanoate dehydrogenase.

3. The non-naturally occurring microbial organism of claim 1 , wherein the exogenous nucleic acids encode a) an α-ketoglutarate dehydrogenase and a CoA-dependent succinic semialdehyde dehydrogenase, and b) a 4-hydroxybutanoate dehydrogenase.

4. The non-naturally occurring microbial organism of claim 1 , wherein the exogenous nucleic acids encode a) a glutamate:succinate semialdehyde transaminase and a glutamate decarboxylase, and b) a 4-hydroxybutanoate dehydrogenase.

5. The non-naturally occurring microbial organism of claim 1 , wherein said monomeric 4-HB is expressed at an intracellular concentration of about 5 mM or more.

6. The non-naturally occurring microbial organism of claim 1 , wherein said monomeric 4-HB is expressed at an intracellular concentration of about 10 mM or more.

7. The non-naturally occurring microbial organism of claim 1 , wherein said microbial organism is a bacterium.

8. The non-naturally occurring microbial organism of claim 1 , wherein the bacterium is Escherichia coli.

9. A method for the production of 4-hydroxybutanoic acid (4-HB) comprising culturing the non-naturally occurring microbial organism of claim 1 under conditions and for a sufficient period of time to produce monomeric 4-HB.

10. The method of claim 9 , wherein the exogenous nucleic acids encode a) an α-ketoglutarate decarboxylase, and b) a 4-hydroxybutanoate dehydrogenase.

11. The method of claim 9 , wherein the exogenous nucleic acids encode a) an α-ketoglutarate dehydrogenase and a CoA-dependent succinic semialdehyde dehydrogenase, and b) a 4-hydroxybutanoate dehydrogenase.

12. The method of claim 9 , wherein the exogenous nucleic acids encode a) a glutamate:succinate semialdehyde transaminase and a glutamate decarboxylase, and b) a 4-hydroxybutanoate dehydrogenase.

13. The method of claim 9 , wherein said monomeric 4-HB is expressed at an intracellular concentration of about 5 mM or more.

14. The method of claim 9 , wherein said monomeric 4-HB is expressed at an intracellular concentration of about 10 mM or more.

15. The method of claim 9 , wherein said microbial organism is a bacterium.

16. The method of claim 9 , wherein the bacterium is Escherichia coli.

17. The method of claim 9 , further comprising the step of isolating the 4-HB.

18. The method of claim 17 , wherein the isolated 4-HB is a salt form.

19. The method of claim 18 , wherein the salt form is a sodium salt.

20. The method of claim 18 , wherein the salt form is a potassium salt.

21. The method of claim 17 , wherein the isolated 4-HB is an acid.

22. The method of claim 17 , wherein the 4-HB is isolated by solvent extraction.

23. A method for producing γ-butyrolactone (GBL), comprising chemically converting 4-HB to GBL, wherein the 4-HB is produced by the method of claim 9 and wherein the GBL is produced by fermentation.

24. A method for producing tetrahydrofuran (THF), comprising chemically converting 4-HB to THF, wherein the 4-HB is produced by the method of claim 9 , and wherein the THF is produced by fermentation and the chemical reduction of 4-HB and/or GBL.

25. A method for producing 1,4-butanediol (BDO), comprising chemically converting 4-HB to BDO, wherein the 4-HB is produced by the method of claim 9 and wherein the BDO is produced by fermentation.

26. A method for producing pyrrolidone, comprising chemically converting 4-HB to pyrrolidone, wherein the 4-HB is produced by the method of claim 9 , and wherein the pyrrolidone is produced by amination of GBL.

27. A method for producing N-methyl-pyrrolidone, comprising chemically converting 4-HB to N-methyl-pyrrolidone, wherein the 4-HB is produced by the method of claim 9 , and wherein the N-methyl-pyrrolidone is produced by amination of GBL.

Assignments (3)
SECURITY INTEREST Recorded Feb 10, 2026
From: GENOMATICA, INC.
To: AGAIN BIO APS
Reel/Frame 074708/0001 →
SECURITY INTEREST Recorded Dec 9, 2025
From: GENOMATICA, INC.
To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT
Reel/Frame 073915/0027 →
SECURITY INTEREST Recorded Jun 2, 2025
From: GENOMATICA, INC.
To: OXFORD FINANCE LLC
Reel/Frame 071471/0770 →
Continuity (7)
Continuation 14603174 · Jan 22, 2015
Continuation 13717350 · Dec 17, 2012
Continuation 13348564 · Jan 11, 2012
Continuation 13286135 · Oct 31, 2011
Continuation 12049256 · Mar 14, 2008
Provisional Application 60918463 · Mar 16, 2007
Related Publication 20170088840A1 · Mar 30, 2017